SCHEMBL2496522

SCHEMBL2496522

CCOC(=O)c1cccc(Nc2ncc(N)cn2)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.67
NPC1 O15118 3/20 0.67
RAB9A P51151 3/20 0.67
KDM4E B2RXH2 1/20 0.67
TYK2 P29597 2/20 0.60
JAK1 P23458 1/20 0.60
BRAF P15056 1/20 0.59
CDC25B P30305 4/20 0.59
MAPT P10636 4/20 0.57
LMNA P02545 2/20 0.57
POLB P06746 1/20 0.57
TP53 P04637 3/20 0.57
HPGD P15428 2/20 0.57
THRB P10828 1/20 0.55
FGFR1 P11362 1/20 0.53
SYK P43405 1/20 0.53
HTR1A P08908 1/20 0.53
HTR1D P28221 1/20 0.53
HTR2A P28223 1/20 0.53
HTR2C P28335 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL656353 0.82 SYK (0.65) SMN1; SMN2NPC1RAB9AKDM4ETYK2
SCHEMBL27631847 0.81 SMN1; SMN2 (0.58) SMN1; SMN2NPC1RAB9AKDM4EBRAF
SCHEMBL6797722 0.81 CDC25B (0.63) SMN1; SMN2NPC1RAB9AKDM4ETYK2
SCHEMBL27929015 0.80 SMN1; SMN2 (0.64) SMN1; SMN2NPC1RAB9AKDM4ETYK2
SCHEMBL14292901 0.80 HPGD (0.59) SMN1; SMN2NPC1RAB9AKDM4EBRAF
SCHEMBL9335965 0.80 CDC25B (0.65) SMN1; SMN2NPC1RAB9AKDM4ETYK2
SCHEMBL13897543 0.79 SMN1; SMN2 (0.63) SMN1; SMN2NPC1RAB9AKDM4ETYK2
SCHEMBL27946422 0.79 SMN1; SMN2 (0.63) SMN1; SMN2NPC1RAB9AKDM4ETYK2
SCHEMBL3697439 0.79 HDAC6 (0.57) SMN1; SMN2NPC1RAB9AKDM4EMAPT
SCHEMBL12651578 0.78 SMN1; SMN2 (0.58) SMN1; SMN2NPC1RAB9AKDM4EBRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 US disclosed
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 US disclosed
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 US disclosed
WO-2008008234-A1 2-AMINO-5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-17 WO disclosed
WO-2008008234-A1 2-AMINO-5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS KDR, FLT4, FLT1 SMN1; SMN2 4812/4885NPC1 4681/4885RAB9A 3189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.